Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor.

Abstract

STUDY DESIGN:

C6 glioma cells and an intramedullary spinal cord tumor model were used to evaluate the effect of bevacizumab (Avastin) or temozolomide (TMZ).

OBJECTIVE:

In this study, we hypothesized that treatment with bevacizumab accelerates the therapeutic effect of TMZ on intramedullary gliomas in an animal model.

SUMMARY OF BACKGROUND DATA:

Recently therapies for the management of intramedullary malignant gliomas include surgery, chemotherapy, and radiotherapy. Concurrent or adjuvant TMZ has been considered an emerging new treatment for intramedullary malignant gliomas; however, high-dose application of TMZ has limitation of side effect.

METHODS:

C6 glioma cells were injected into the T5 level of the spinal cord, and TMZ and bevacizumab were administered 5 days after C6 inoculation (n = 7 for each group). Tumor size was analyzed using histology and magnetic resonance imaging at 13 days after tumor inoculation.

RESULTS:

Histological analyses and magnetic resonance imaging findings showed that combined treatment with TMZ and bevacizumab reduced tumor mass. The tumor volume of control group was 2.8-fold higher than combined therapy (P < 0.05). Neurological outcomes demonstrated that combined therapy improved hind limb function more than TMZ-alone group or control group (P < 0.05).

CONCLUSION:

This study shows that bevacizumab could be useful in combination with TMZ to increase the therapeutic benefits of TMZ for intramedullary spinal cord tumors.

LEVEL OF EVIDENCE:

N/A.

• Authors: So-Jung Gwak, Sung Su An, Moon Sul Yang, Eunhae Joe, Dong-Hyun Kim, Do Heum Yoon, Keung Nyun Kim, Yoon Ha
• Journal: Spine (Spine (Phila Pa 1976)) Vol. 39 Issue 2 Pg. E65-73 (Jan 15 2014) ISSN: 1528-1159 [Electronic] United States
• PMID: 24158177 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Dacarbazine
• Temozolomide

Topics

• Animals
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Bevacizumab
• Cell Line, Tumor
• Dacarbazine (administration & dosage, analogs & derivatives)
• Male
• Rats
• Rats, Sprague-Dawley
• Spinal Cord Neoplasms (drug therapy, pathology)
• Temozolomide
• Treatment Outcome